StreetInsider.com News Articles

Immunome doses first patient in Phase 1 trial of FAP-targeted therapy

Mon, 20 Jul 2026 07:30:09 -0400

Immunome, Inc. (Nasdaq: IMNM) announced that the first patient has been dosed in a Phase 1, first-in-human trial of IM-3050, an investigational radioligand therapy targeting fibroblast activation protein (FAP) in patients with FAP-expressing advanced solid tumors.

IM-3050 is designed to deliver radioactive lutetium-177 directly to FAP-expressing cells, where emitted beta particles may damage or kill nearby tumor cells through a bystander effect. FAP is expressed on cancer-associated fibroblasts in the tumor microenvironment.

The open-label, multicenter trial will evaluate the safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity of IM-3050. The dose escalation portion will assess escalating repeated doses to determine the maximum

Immunome doses first patient in Phase 1 trial of FAP-targeted therapy

Mon, 20 Jul 2026 07:30:09 -0400

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

Mon, 20 Jul 2026 07:30:00 -0400

IM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells.
The Phase 1 trial is designed to evaluate the safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity of IM-3050 in participants with FAP-expressing advanced solid tumors.

BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-3050, an investigational FAP-targeted radioligand therapy being evaluated in patients with FAP-expressing advanced solid

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

Mon, 20 Jul 2026 07:30:00 -0400

IM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells.
The Phase 1 trial is designed to evaluate the safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity of IM-3050 in participants with FAP-expressing advanced solid tumors.

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

Mon, 20 Jul 2026 07:30:00 -0400

IM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells.
The Phase 1 trial is designed to evaluate the safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity of IM-3050 in participants with FAP-expressing advanced solid tumors.

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

Mon, 20 Jul 2026 07:30:00 -0400

IM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells.
The Phase 1 trial is designed to evaluate the safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity of IM-3050 in participants with FAP-expressing advanced solid tumors.

Form 4 Immunome Inc. For: Jul 07 Filed by: Horn Kinney

Thu, 09 Jul 2026 17:38:00 -0400

si-local-file:///var/storage/secattach/20260709/26754035.html

Form 4 Immunome Inc. For: Jul 07 Filed by: Horn Kinney

Thu, 09 Jul 2026 17:38:00 -0400

si-local-file:///var/storage/secattach/20260709/26754035.html

H.C. Wainwright Reiterates Buy Rating on Immunome Inc. (IMNM)

Thu, 09 Jul 2026 06:48:43 -0400

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating and $40.00 price target on Immunome Inc. (NASDAQ: IMNM).

The analyst commented: "The FDA has accepted Immunome’s NDA for varegacestat with a PDAFU date of April 28th, 2027. The filing is supported by the Phase 3 RINGSIDE trial data which met its primary PFS endpoint with an 84% reduction in risk of progression (HR 0.16, p<0.0001) and showed a 56% ORR vs. 9% placebo (p<0.0001) alongside a faster median time to response and reduction in tumor volume (83% at week 24 vs. +11% in placebo). The PFS benefit held consistently across

FDA accepts Immunome drug application for desmoid tumor treatment

Wed, 08 Jul 2026 07:30:14 -0400

Immunome, Inc. (Nasdaq: IMNM) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for varegacestat, an investigational oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act target action date of April 28, 2027.

The NDA is based on results from the Phase 3 RINGSIDE trial, which enrolled 156 patients with progressing desmoid tumors. The trial met its primary endpoint, showing an 84% reduction in the risk of disease progression or death compared with placebo, with a hazard ratio of 0.16 (p<0.0001). The objective response

FDA accepts Immunome drug application for desmoid tumor treatment

Wed, 08 Jul 2026 07:30:14 -0400

FDA accepts Immunome drug application for desmoid tumor treatment

Wed, 08 Jul 2026 07:30:14 -0400

FDA accepts Immunome drug application for desmoid tumor treatment

Wed, 08 Jul 2026 07:30:14 -0400

FDA accepts Immunome drug application for desmoid tumor treatment

Wed, 08 Jul 2026 07:30:14 -0400

FDA accepts Immunome drug application for desmoid tumor treatment

Wed, 08 Jul 2026 07:30:14 -0400

FDA accepts Immunome drug application for desmoid tumor treatment

Wed, 08 Jul 2026 07:30:14 -0400

FDA accepts Immunome drug application for desmoid tumor treatment

Wed, 08 Jul 2026 07:30:14 -0400

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors